Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CHMA Chiasma (CHMA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Chiasma Stock (NASDAQ:CHMA) 30 days 90 days 365 days Advanced Chart Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Chiasma alerts:Sign Up Key Stats Today's Range$3.76▼$3.7650-Day Range$3.76▼$4.7152-Week Range$2.77▼$5.74Volume147 shsAverage Volume2.12 million shsMarket Capitalization$217.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Read More… 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Receive CHMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter. Email Address CHMA Stock News HeadlinesChiasma Craters on FDA Drug RejectionOctober 29, 2023 | thestreet.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027 - GlobeNewswireOctober 6, 2022 | globenewswire.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 21, 2024 | Crypto 101 Media (Ad)Ironshore Announces Executive Appointments and Strengthening of the Global Business Management Team - Business WireSeptember 28, 2022 | businesswire.comCHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly - Marketscreener.comSeptember 16, 2022 | marketscreener.comAmryt (AMYT) Receives Positive CHMP Opinion for Mycapssa - StreetInsider.comSeptember 16, 2022 | streetinsider.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 - Yahoo Finance UKSeptember 7, 2022 | uk.finance.yahoo.comMPM ASSET MANAGEMENT LLC Buys - GuruFocus.comAugust 12, 2022 | gurufocus.comSee More Headlines CHMA Stock Analysis - Frequently Asked Questions How were Chiasma's earnings last quarter? Chiasma, Inc. (NASDAQ:CHMA) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.18. The biotechnology company had revenue of $1.92 million for the quarter, compared to analyst estimates of $1.80 million. When did Chiasma IPO? Chiasma (CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers. What other stocks do shareholders of Chiasma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), Meta Platforms (META), GW Pharmaceuticals (GWPH), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and TherapeuticsMD (TXMD). Company Calendar Last Earnings5/06/2021Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CHMA CUSIPN/A CIK1339469 Webwww.chiasmapharma.com Phone617-928-5300FaxN/AEmployees85Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-113.57% Return on Assets-57.62% Debt Debt-to-Equity RatioN/A Current Ratio7.91 Quick Ratio7.08 Sales & Book Value Annual Sales$1.11 million Price / Sales196.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book2.36Miscellaneous Outstanding Shares57,894,000Free FloatN/AMarket Cap$217.68 million OptionableNot Optionable Beta1.28 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:CHMA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chiasma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chiasma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.